Although the identification of the driver mutations of JAK2, CALR, and MPL found in the majority of MPN (excluding triple-negative cases) has provided substantial insight into the pathogenesis of Ph− MPN, one of the highest unmet clinical needs is the paucity of biomarkers that reliably predict the disease course. This evidence concerns the gene MPL and myeloproliferative neoplasm.